Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug ONO-7428 enters first human tests for advanced cancers

NCT ID NCT06816108

Ongoing Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be monitored for side effects and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC SOLID TUMOR

Contacts and locations

Locations

  • Hyogo Medical University Hospital

    Nishinomiya, Hyōgo, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Kansai Medical University Hospital

    Hirakata, Osaka, Japan

  • Kindai University Hospital

    Sakai, Osaka, Japan

  • Kitasato University Hospital

    Sagamihara, Kanagawa, Japan

  • Kochi Medical School Hospital

    Nankoku, Kochi, Japan

  • Kurume University Hospital

    Kurume, Fukuoka, Japan

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • Saitama Cancer Center

    Shinden, Saitama, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan

  • The Cancer Institute Hospital Of JFCR

    Koto-Ku, Tokyo, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

    Bunkyō-Ku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.